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Abstract
Background: DAS28 is interpreted as the inflammatory disease activity of RA. Non-inflammatory pain mechanisms
can confound assessment. We aimed to examine the use of DAS28 components or DAS28-derived measures that
have been published as indices of non-inflammatory pain mechanisms, to inform interpretation of disease activity.
Methods: Data were used from multiple observational epidemiology studies of people with RA. Statistical characteristics
of DAS28 components and derived indices were assessed using baseline and follow up data from British Society for
Rheumatology Biologics Registry participants (1) commencing anti-TNF therapy (n= 10,813), or (2) changing between
non-biologic DMARDs (n = 2992), (3) Early Rheumatoid Arthritis Network participants (n= 813), and (4) participants in a
cross-sectional study exploring fibromyalgia and pain thresholds (n = 45). Repeatability was tested in 34 patients with
active RA. Derived indices were the proportion of DAS28 attributable to patient-reported components (DAS28-P),
tender-swollen difference and tender:swollen ratio. Pressure pain detection threshold (PPT) was used as an index of
pain sensitisation.
Results: DAS28, tender joint count, visual analogue scale, DAS28-P, tender-swollen difference and tender:swollen ratio
were more strongly associated with pain, PPT and fibromyalgia status than were swollen joint count or erythrocyte
sedimentation rate. DAS28-P, tender-swollen difference and tender:swollen ratio better predicted pain over 1 year than
did DAS28 or its individual components.
Conclusions: DAS28 is strongly associated both with inflammation and with patient-reported outcomes. DAS28-derived
indices such as tender-swollen difference are associated with non-inflammatory pain mechanisms, can predict future pain
and should inform how DAS28 is interpreted as an index of inflammatory disease activity in RA.
Background
The 28 joint disease activity score incorporating erythro-
cyte sedimentation rate (DAS28-ESR) is widely used as a
measure of inflammatory disease activity in people with
RA during clinical decision-making. In the UK, DAS28-
ESR is used to determine eligibility for biologic therapies
[1]. DAS28-ESR ≥3.2 can be used as a threshold for
classifying active RA, and DAS28 is often used in clinical
trials [2], or as a target for intensive treatment [3].
Current evidence supports these approaches as outcome
measures in people with RA [4, 5].
Non-inflammatory mechanisms, through their effects
on pain, can confound interpretation of DAS28-ESR ≥3.2
as a measure of active inflammation. Swollen joint count
(SJC) and ESR are markers of inflammation. However,
tender joint counts (TJCs) might be increased in people
with centrally augmented pain, and the visual analogue
scale for global health (VAS-GH) might be high in people
fulfilling fibromyalgia (FM) classification [6, 7]. Persistent
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non-inflammatory pain can result in patients in remission
being misclassified as having active inflammatory disease,
leading to inappropriate clinical decisions to escalate ther-
apy. Persistent non-inflammatory pain might compromise
interpretation of outcomes in clinical trials. Furthermore,
clinical tools that identify the subgroup of people with
high DAS28 who also have high inflammation (rather than
non-inflammatory pain) could help select people for inclu-
sion in clinical trials or for anti-inflammatory treatment.
Several indices have been derived from DAS28-ESR
components in an attempt to measure non-inflammatory
contributions in people with RA. Pollard et al. have shown
an association between tender minus swollen joint count
(tender-swollen difference) and concurrent FM status or
increased pain sensitivity [8]. We reported DAS28-P, de-
fined as the proportion of DAS28-ESR attributable to
patient-reported components (TJC and VAS-GH) [9].
DAS28-P was associated with pain severity, and predicted
future pain in early RA [9], and in people commencing or
changing biologic or non-biologic disease modifying treat-
ments [10]. DAS28-P was also associated with increased
pain sensitivity and concurrent FM in people with RA [7].
Evidence from one national registry suggested that the ra-
tio of tender to swollen joint counts (tender:swollen ratio)
might predict less good response of RA to biologic therapy
[11], after being trichotomised into three groups. Each of
these derived indices attempts to estimate the discordance
between patient-reported symptoms and observed or la-
boratory measured inflammation. Other symptoms such
as anxiety, depression and fatigue are strongly associated
with chronic pain, and might reflect overlapping mecha-
nisms within the central nervous system in people with
RA [12]. We hypothesised that derived indices are associ-
ated with non-inflammatory pain and with patient-
reported outcome measures of mental health and vitality
or fatigue.
We sought to better understand DAS28-ESR, its com-
ponents and the published derived indices in order to in-
form interpretation of non-inflammatory mechanisms in
RA. To achieve this, we examined:- (1) The statistical
properties of each index to show how each may be used
in statistical analyses, including distribution (to show
their continuum of values) and variability of repeat mea-
surements (higher repeatability between clinicians im-
proves the validity of a measure). (2) Associations of
each index with pain and related patient-reported out-
comes, and markers of central pain mechanisms, which
are the primary objectives of their derivation. (3) Associ-
ation with inflammatory disease activity (because indices
of non-inflammatory mechanisms should not necessarily
increase with increasing inflammation). (4) Prediction of
future pain (non-inflammatory pain mechanisms might
not be responsive to DMARD therapy and their pres-
ence might therefore predict poor pain prognosis).
Methods
Datasets from four published studies were used to explore
statistical characteristics of DAS28 components and de-
rived indices of inflammatory or non-inflammatory dis-
ease activity; baseline data collected from participants in
the British Society for Rheumatology Biologics Register
(BSRBR) with active, established RA and a valid DAS28-
ESR score who were (1) initiating anti-TNF therapy
(BSRBR anti-TNF cohort; n = 10,813) [13], or (2) changing
between non-biologic disease modifying anti-rheumatic
drugs (DMARDs, BSRBR-Control cohort; n = 2992) [14],
(3) participants in the Early Rheumatoid Arthritis
Network (ERAN cohort; n = 813) [15], and (4) participants
undergoing routine care in a hospital-based, cross sec-
tional study exploring FM status and pain pressure thresh-
olds (PPT group; n = 45) [7]. Written informed consent
was obtained from all participants. Data were used only
for participants with active disease, as defined by a
DAS28-ESR ≥3.2. The PPT group included only complete
case data available for all variables. Repeatability of the
variables was determined from DAS28 assessments per-
formed by multiple assessors in people with RA during
training sessions completed during practice standardisa-
tion for clinicians in the ERAN study.
The BSRBR anti-TNF cohort is a national register,
started in 2002 that tracked biologic naïve people with
RA commencing their first anti-TNF agent. The BSRBR
control cohort is a multicentre longitudinal study of
people with RA who were changing to a new non-
biologic treatment at recruitment, and was intended for
use as a comparator to biologic cohorts. Both cohorts
are coordinated by the University of Manchester. The
BSRBR cohorts were approved by NHS North West
Multicentre Research Ethics Committee (00/8/53). Base-
line data were provided to the authors in de-identified,
anonymous formats with no indication of the anti-TNF
agent being used, nor the dates of enrolment and treat-
ment. ERAN was a multicentre inception cohort study
of newly diagnosed RA spanning the UK and Eire and
commenced recruitment in 2002. The study was ap-
proved by Trent Research Ethics Committee (01/4/047).
Baseline and follow up data up to 1 year were used in
the current study. Participants in a hospital-based study
of pain pressure thresholds and pain mechanisms in
people with RA were recruited through routine annual
outpatient appointments for RA management at
Sherwood Forest Hospitals NHS Foundation Trust [7].
Ethical approval for this project was obtained from the
East Midlands NREC – Nottingham 2 (13/EM/0047).
Participants with RA were eligible for inclusion if their
DAS28-ESR ≥ 3.2.
Alterations and rearrangements of the DAS28 formula
might possibly increase the variation in the derived
scores compared to DAS28-ESR. Repeatability data were
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derived from DAS28-ESR assessments taken on the
same day for each patient by each assessor across four
clinical assessment training classes for rheumatology re-
searchers. The total repeatability group contained 34
people with RA across the four sessions. People with RA
were assessed in subgroups of 2–4, each individual
assessed on two occasions separated by > 1 h by each of
3 to 7 rheumatology healthcare workers. Data were com-
bined with single ESR measurements per individual to
give DAS28-ESR or DAS28-P scores. Repeat measures of
VAS-GH were available for a subset of 19 people with
RA, while the remainder rated VAS-GH once.
The formulae for derived indices were:
DAS28‐P ¼ 0:56√TJCþ 0:014VAS−GH =DAS28‐ESR
Tender‐swollen difference ¼ TJC–SJC
Tender : swollen ratio ¼ TJC=SJC
Participants completed a range of self-report question-
naires addressing symptoms. Bodily Pain, Vitality and Mental
Health were assessed in BSR-BR and ERAN groups using
Short Form-36 (SF36) and norm-transformed values used
for this study (SF36 subscales are negatively oriented, with
lower scores reflecting worse quality of life). PPT participants
completed the Beck Depression Inventory (BDI) [16]; State-
Trait Anxiety Index short form (STAI-SF) [17]; Fatigue
Severity Scale (FSS) [18]; Widespread Pain Index (WPI) [19];
Symptom Severity Scale (SSS) [20]. WPI and SSS question-
naires permitted FM classification according to American
College of Rheumatology criteria 2010 [20].
PPT testing used an electronic pressure algometer
with a laptop recording/display device and a patient
switch (Somedic Sensebox). It was carried out by a sin-
gle, trained observer (NJ) at the anterior tibia [7]. Low
PPT (greater sensitivity) distant from affected joints is
taken as an index of widespread (possibly central)
sensitization.
CRP was included as a covariate marker of concurrent
inflammatory disease activity that was not included in any
of the derived indices. CRP was measured by clinical la-
boratories local to recruiting centres. Reported CRP values
< 5 mg/ml were imputed with the value of 4 mg/ml. Ln-
transformation of CRP was used to adjust for inflamma-
tion as a covariate and for regression analyses, because it
displayed closer approximation to normality on Q-Q plots
than did non-transformed CRP (data not shown).
Statistical analysis
Repeatability was assessed by calculating the inter-observer
measures of the same patient volunteer performed on the
same day. The average coefficient of variation (CV;
calculated as sd/mean) was calculated for each different
measurement or index, as recommended as a measure of
precision error [21], and is presented as a percentage.
Differences between groups were assessed using T-tests
and Cohen’s d effect size. Skewness and kurtosis were
calculated for each variable [22]. Normality of distributions
was assessed by Q-Q plots. For regression analyses, square
root transformations of TJC and SJC; and natural
logarithms were used for tender:swollen ratio and ESR.
Cross-sectional, baseline-only associations of DAS28-
ESR, components or derived indices, transformed where
necessary, with other outcomes were determined by
linear regression of standardised variables providing B
coefficients (95% CI) that could be compared between
and across variables. Longitudinal analyses with General-
ised Estimating Equations (GEE) used data from baseline
to predict 3–6 month and 1 year SF36-Bodily Pain
scores. The analyses were controlled for similar variables
to other analyses of longitudinal pain performed in
ERAN and BSRBR cohorts [9, 23], such as common
disease markers for RA severity (disability, serology and
disease duration), demographics or lifestyle (age, gender,
BMI, smoking) and pain-related factors (mental health
and fatigue). The effects of inflammation were adjusted
for using CRP measures, as this was the available
measure that was the most-independent compared to
the other DAS28-ESR components. Analysis was
performed using SPSS v22 (IBM, USA) and p < 0.05 was
taken as statistical significance.
Results
Demographics of each patient group are shown in
Table 1. As expected, fewer participants satisfied 1987
ACR RA classification criteria in ERAN at baseline than
in those other groups recruited from people with
established RA. The BSRBR anti-TNF group displayed
highest scores for DAS28 and its components.
Measurement properties of DAS28-ESR, its components
and derived indices
Tender:swollen ratio underwent logarithmic transform-
ation to give a closer approximation to a normal
distribution (which improves its measurement proper-
ties; Additional file 1: Figure S1 and Table S1).
Transformed tender:swollen ratio data were therefore
used in all analyses. Some measurements displayed
prominent floor and ceiling effects. The proportions of
cases that displayed either maximum or minimum
scores were highest for tender:swollen ratio (≤15% mini-
mum and ≤ 28% maximum depending upon participant
group). SJCs were zero in 28% of PPT study, and 7% of
ERAN participants, but ≤1% in BSRBR cohorts. Of
BSRBR-anti-TNF cohort participants, 6% displayed SJC
= 28, and 6% displayed VAS-GH = 100 mm. Other
measures all showed ≤3% floor or ceiling prevalence.
Inter-observer repeatability was indicated by coefficients
of variation; TJC (41%), VAS-GH (16%), SJC (62%),
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DAS28-P (17%), tender-swollen difference (188%) and
tender:swollen ratio (64%).
Associations with pain and other patient-reported
outcomes
DAS28-ESR and its components and each of the derived in-
dices were significantly associated with Bodily Pain scores in
each participant group (Additional file 1: Table S2). Cross-
sectional associations with Bodily Pain scores were adjusted
for CRP to explore possible dependence on non-
inflammatory factors (Additional file 1: Table S3). Each
study group showed multiple significant associations of
worse Bodily Pain scores with DAS28-ESR, and also with
the DAS28-ESR components TJC and VAS-GH. Bodily Pain
scores were also significantly associated with DAS28-P;
tender-swollen difference; and tender:swollen ratio. Less
consistent findings were found for ESR and SJC.
Lower PPTs (more sensitive) at the anterior tibia were
significantly associated with higher TJC, VAS-GH, DAS28-
ESR, and DAS28-P. Lower PPTs were also significantly
associated with tender-swollen difference, but not with SJC,
ESR nor tender:swollen ratio (Table 2). DAS28-ESR, TJC,
VAS-GH, DAS28-P and tender-swollen difference were
higher in participants that satisfied criteria for FM, whereas
SJC, ESR and tender:swollen ratio were not (Table 2).
Higher DAS28-ESR was associated with worse mental
health, as measured by BDI (depression) or STAI-SF
(anxiety), or SF36Mental Health Score (distress; Table 3A).
Higher DAS28-ESR was also associated with worse fa-
tigue/lower vitality in each group (Table 3B). Associations
with worse mental health or fatigue were stronger for
VAS-GH and TJC than for SJC and ESR, and more
consistently significant for DAS28-P and tender-swollen
difference than for tender:swollen ratio (Table 3A, B).
Associations between DAS28-related variables, DAS28-
ESR and CRP
Indices of non-inflammatory pain might be expected to
be independent of inflammation levels. Each individual
DAS28-ESR component and derived index displayed the
Table 1 Demographics and clinical features of participant groups at baseline
ERAN BSRBR anti-TNF BSRBR-Control PPT study Repeatability
N= 813 10,813 2992 45 34
%female 70% 76% 74% 77% 73%
Age (mean (sd)) 57 (14) 56 (12) 60 (12) 60 (11) 60 (13)
Seropositive 59% 65% 58% 90% 79%
DAS28-ESR 5.2 (1.1) 6.6 (1.0) 5.4 (1.1) 4.7 (0.9) 4.8 (1.1)
ESR 34 (24) 46 (29) 37 (25) 21 (13) 39 (29)
SJC 7 (6) 11 (6) 6 (5) 1 (1) 5 (4)
TJC 9 (7) 16 (7) 9 (7) 11 (7) 6 (6)
VAS-GH 50 (24) 73 (20) 57 (23) 53 (23) 39 (20)
CRP 28 (37) 46 (42) 35 (40) < 5 not collected
Eligible population: proportion (number) of cases from database with DAS28-ESR ≥ 3.2 and therefore included in this study. TJC tender joint count, SJC swollen
joint count, ESR erythrocyte sedimentation rate, VAS-GH visual analogue scale-general health, CRP C-reactive protein (mg per dL)
Table 2 Associations of DAS28-related variables with pressure pain thresholds and fibromyalgia classification
Index Medial Tibia PPT Fibromyalgia (FM) classification
B (95% CI) p RA with FM RA (no FM) p Difference Effect size
TJC − 0.39 (− 0.63 to − 0.15) 0.002 14 (7) 8 (6) 0.01 5.3 0.75
VAS-GH − 0.37 (− 0.61 to − 0.13) 0.003 67 (19) 42 (19) < 0.001 25 1.09
SJC 0.03 (− 0.23 to 0.28) 0.834 1 (1) 1 (2) 0.742 0.15 0.1
ESR −0.10 (− 0.36 to 0.17) 0.464 23 (16) 20 (11) 0.51 2.7 0.2
DAS28 − 0.53 (− 0.77 to − 0.29) < 0.001 5.2 (0.8) 4.4 (0.8) 0.001 0.79 0.93
DAS28-P −0.41 (− 0.62 to − 0.13) 0.003 0.56 (0.11) 0.48 (0.09) 0.008 0.09 0.81
Tender-swollen difference −0.38 (− 0.62 to − 0.15) 0.002 12 (8) 7 (6) 0.011 5.5 0.76
Tender:swollen ratio −0.48 (− 0.79 to − 0.18) 0.003 8.4 (7.0) 6.2 (5.9) 0.363 2.1 0.33
Data from PPT study, n = 45. Linear regression between medal tibial pressure pain thresholds (PPT) and DAS28-related variables (lower values of PPTs indicate
greater pain sensitivity). Means (sd); T-Tests and Cohens d effect size for differences between patients with RA ± fibromyalgia (FM). TJC tender joint count,
SJC swollen joint count, ESR erythrocyte sedimentation rate, VAS-GH visual analogue scale-general health. DAS28-P = proportion of DAS28-ESR attributable to
patient-reported components. No corrects were performed for multiple comparisons. Statistically significant findings highlighted in bold
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expected significant positive associations with DAS28-
ESR in each participant group (Table 4). Associations of
each derived index with DAS28-ESR appeared to have
smaller coefficients than those of the individual DAS28-
ESR components (Table 4). The weakest association of
DAS28-ESR was with tender:swollen ratio. The expected
positive associations were found between DAS28-ESR
components and serum CRP level. Conversely, none of
the derived indices displayed significant positive
correlation with serum CRP (Table 4). DAS28-P was
significantly negatively associated with serum CRP level
in all groups, whereas negative associations with tender-
swollen differences and tender:swollen ratios were
weaker than with DAS28-P (Table 4).
Longitudinal prediction of pain
The longitudinal prediction of pain was tested for each
of the DAS28-ESR components and derived indices
using GEE analyses. Baseline DAS28-ESR, derived
indices and DAS28-ESR components each predicted
worse pain prognosis up to 1 year in univariate analyses
(Table 5). Baseline tender-swollen difference and
tender:swollen ratio were significantly associated with
worse pain prognosis in all longitudinal cohorts using
multivariable GEE analysis adjusting for baseline pain,
inflammation measured by CRP, and other potential
confounders (Table 5). High DAS28-P was significantly
associated with worse pain prognosis in ERAN and
BSRBR non-biologic cohorts, but not in the BSRBR anti-
TNF cohort after multivariable analysis (Table 5).
Associations of DAS28-ESR, SJC, TJC or VAS-GH with
pain prognosis was significant in only one of the three
cohorts for each (Table 5).
Discussion
We have shown that indices derived from DAS28-ESR
components can give insight into the non-inflammatory
contributions to apparent inflammatory disease activity
in people with RA. Tender-swollen difference might
have some advantages over other derived indices,
although head-to-head statistical comparisons were not
made. Derived indices were consistent with being
measures of non-inflammatory factors, as they were less
strongly associated with DAS28-ESR than were individ-
ual DAS28-ESR components; and tender-swollen
difference was not consistently associated with CRP.
Tender-swollen difference and DAS28-P each was
positively associated with FM status, and with PPT
evidence of neuronal sensitisation, as found previously
[8, 24]. They displayed normal-like distributions and
were without notable floor or ceiling effects. Tender-
swollen difference more consistently predicted pain
outcomes than did DAS28-P. DAS28-derived indices
have potential as research tools, to help interpret
DAS28-ESR as a measure of inflammatory disease activ-
ity, and to help predict those who might benefit from
additional interventions aiming to reduce the long-term
burden of pain in people with RA.
DAS28-ESR is an important measure of inflammatory
disease activity in RA [25–29]. Our analyses confirm a
strong association between DAS28-ESR or its components
and self-reported pain, as would be expected where in-
flammation drives RA symptoms. However, VAS-GH and
TJC, and therefore DAS28-ESR, are strongly influenced by
non-inflammatory pain mechanisms [7]. Some authors
have found benefits from analysing SJC + ESR combined
and contrasting to TJC + VAS-GH combined. This may be
a way to further examine people in clinical remission with
low inflammation, but high pain [30]. Furthermore, as
DAS28 shares many components with the Clinical Disease
Activity Index [31] and the Simplified Disease Activity
Index [32], plus some of the criteria for Boolean
Remission [33], there may be scope for cross-validation
between different indices.
We have shown that indices derived from DAS28-ESR
components are associated with pain, while displaying
little dependence on inflammation, as measured by CRP.
In cross-sectional analyses, DAS28-ESR and the derived
indices were similarly associated with pain and other
symptoms. However, each of the derived indices pre-
dicted 1 year pain prognosis more strongly than did
DAS28-ESR or each of its components. However, exam-
ining the exact mechanisms for pain prognosis is a com-
plex task. Modern treatment, including biologic
therapies, might counteract the importance of synovitis
for pain prognosis. Pain might be more likely to persist
where non-inflammatory mechanism make an important
contribution and therefore pain outcomes might be best
predicted by derived indices that reflect those non-
inflammatory mechanisms.
Our data extend previous findings that DAS28-P
predicted pain following initiation of biologic or non-
biologic DMARDS [9], and that swollen:tender ratio
predicted response to biologic treatment [11]. We
demonstrate prediction of pain outcomes also by tender-
swollen difference, and that pain prediction by derived
indices persists after adjusting for other baseline
demographic and clinical factors known to influence
pain, including measures of inflammatory disease
activity, psychological distress, obesity and smoking
status.
We found that pain prediction by baseline values of de-
rived indices were weaker in the BSRBR anti-TNF cohort
than in the other two studies, consistent with our previous
analyses [9, 10]. It is possible that TNF blockade inhibits
non-inflammatory as well as inflammatory pain mecha-
nisms [34], or that more effective suppression of an in-
flammatory drive to central sensitisation might also
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inhibit non-inflammatory pain mechanisms [35]. Con-
founding by the higher baseline RA severity in the BSRBR
biologics cohort might also contribute to differences in
pain prediction. DAS28-P did not predict EULAR-defined
inflammatory disease responses 3 months after initiation
of biologic therapy in another study [36], and factors that
predict pain response to treatment might differ from those
predicting inflammatory disease suppression.
Low PPTs indicate neuronal sensitisation and, when
observed at a distance from affected joints, might reflect
central sensitisation [37]. Concurrent classification of
FM is common in people with RA [7] and is considered
also to reflect central sensitisation. Derived indices
displayed significant associations with PPTs and FM
classification, suggesting that they might reflect central
sensitisation in RA. Central sensitisation might indicate
comorbid conditions such as FM or result from
sustained nociceptive input from joint inflammation [12]
or other co-morbidities, such as osteoarthritis and low
back pain. We did not observe significant associations
between SJC or ESR and PPTs or FM classification,
indicating that ongoing inflammation might not be
necessary to sustain sensitisation in RA, although
inflammation might yet contribute to the development
of sensitisation in earlier disease.
Self-reported fatigue and poor mental health scores
are associated with worse pain and greater central
sensitisation in people with RA [38, 39]. DAS28-ESR
was significantly associated with fatigue and mental
health in each study group. However, SJC and ESR were
less consistently or less strongly (smaller coefficients) as-
sociated with fatigue or mental health than were TJC
and VAS-GH, paralleling the various associations seen
with bodily pain. Furthermore, we now extend our previ-
ous findings on pain [7] to show that derived indices
were significantly associated with fatigue and mental
health scores in both early and established disease.
Fatigue and/or poor mental health might, therefore, be
additional centrally mediated non-inflammatory mecha-
nisms that confound inflammatory disease assessment
using DAS28-ESR.
Derived indices displayed less positive association with
CRP than did DAS28-ESR or its components, and
therefore have some external validity as measures of
non-inflammatory mechanisms. Testing against
additional measures of inflammation, for example using
ultrasound or magnetic resonance imaging, might fur-
ther extend these findings. Tender-swollen difference
displayed some advantages over the other derived
measures, in being simple to calculate, displaying a
normal distribution without important floor and ceiling
effects, displaying consistent associations with pain, PPT
and FM status, and consistently predicting worse pain
outcome across all three cohort studies. The inclusion of
four items in DAS28-P might improve its validity over
indices derived from only two items, but the significant
negative association of DAS28-P with CRP, possibly due
to the inclusion of ESR in its denominator, suggests po-
tential confounding by inflammation. DAS28-P displayed
a lower coefficient of variation than did the tender-
swollen difference. However, the coefficient of variation
statistic tends towards infinity where mean values
approach zero, and this might underestimate the repeat-
ability of the tender-swollen difference. It showed similar
standardised coefficients and confidence intervals with
other indices, and we believe that it has similar validity
to DAS28-P when used to analyse these data. Inclusion
of a single ESR measurement might also have led us to
overestimate the repeatability of DAS28-P. Tender:-
swollen ratio had a number of disadvantages including
floor and ceiling effects, and skewness that necessitated
transformation prior to parametric analysis. When the
swollen:tender ratio was derived, it was split into three
response levels to deal with the effects of zero values
[11], whereas this analysis focussed on comparisons of
continuous indices. Tender-swollen difference might be
a preferred continuous derived index for studying non-
inflammatory contributions to RA pain.
Our study is subject to several limitations, despite the
availability of data from several large groups with early
or established RA. The consistent pattern of findings for
each index is presented across a variety of data sources.
As most of the comparisons were complementary, no
corrections were made for multiple testing. Derived
indices have value in epidemiology or secondary data
analyses where more specific measures of non-
inflammatory mechanisms such as central sensitisation
are unfeasible or not available. However, their interpret-
ation as surrogates for pain sensitivity or central
sensitisation should be cautious in the context of other
potential confounders such as mental health or fatigue.
In the absence of a gold-standard measure of central
sensitisation or non-inflammatory pain, we have used
PPTs and bodily pain as surrogates. Using other surro-
gate measures might have altered the study findings.
Further research is required to determine which specific
non-inflammatory disease mechanisms modulate assess-
ment of inflammation using DAS28-ESR. Our study
used CRP as a measure of inflammation, although some
patients with RA might have continuing inflammatory
disease activity despite normal CRP, in particular since
the introduction of interleukin-6 blockade. CRP was
selected because it was not included in any of the
DAS28-related variables, and so would be the least likely
to be a confounder. Other measures of synovitis might
reveal possible associations of derived indices with re-
sidual synovitis. Lack of formal reliability data is a
limitation, and necessitated use of CV values. The
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repeatability data are limited by their collection from a
large number of practitioners with varying experience,
and may reflect the “real world” variability, rather than
an optimal variability. CV values of VAS-GH might be
underestimated because it was not possible to blind
participants to previous instructions or responses during
repeated assessment by successive practitioners. It
should be noted that other definitions of disease activity,
treatment response and remission are available [40–42].
Data from observational cohort studies cannot distin-
guish effects on treatment from those on placebo
response or natural history. Future studies should
therefore also test the ability of derived measures to
predict response to treatments within the context of
randomised controlled trials, either targeting synovitis or
non-inflammatory disease mechanisms.
Non-inflammatory contributions are of particular
clinical importance where DAS28-ESR suggests active
inflammatory disease. Overestimation of synovitis might
result in inappropriate exposure of patients to poten-
tially toxic or expensive treatments, and underestimation
of inflammatory disease suppression might lead to
discontinuation of treatments that would otherwise
prevent joint damage and subsequent disability. The
presence of non-inflammatory pain mechanisms does
not, however, exclude concurrent inflammation, and
even moderate disease activity is longitudinally associ-
ated with both poor function and joint damage [28].
Specific measures of synovitis such as ultrasound assess-
ment might help guide treatment titration to achieve
low disease activity or remission in all cases, particularly
where non-inflammatory mechanisms might conceal
contributions of persistent synovitis to DAS28-ESR.
Non-inflammatory mechanisms underlying important
symptoms such as pain, fatigue or impaired mental
health are important even where DAS28-ESR suggests
that inflammation is well controlled. Derived measures
are unlikely to be appropriate in people with remission
of inflammatory disease, where more experimental
measures such as PPT or other forms of quantitative
sensory testing might reveal non-inflammatory pain
mechanisms. Where DAS28-ESR < 3.1, DAS28-P displays a
skewed distribution and high measurement errors are gen-
erated by ratios in which denominators are close to zero [9].
Conclusion
In conclusion, we demonstrate the potential of derived
indices as measures of non-inflammatory mechanisms in
people with apparently active RA (DAS28-ESR ≥ 3.2).
Our analyses suggest that tender-swollen difference,
DAS28-P and tender:swollen ratio are surrogate indices
of non-inflammatory pain mechanisms, and we propose
that central sensitisation is a likely candidate. DAS28-
ESR remains a valuable measure of active synovitis,
which continues to facilitate the development of disease
modifying treatments and helps target treatments those
to those who gain most benefit [4, 5, 43, 44]. Derived
indices, such as tender-swollen difference, conveniently
assist interpretation of DAS28-ESR as a measure of
inflammatory disease activity. With further research to
establish thresholds, they may have potential to help
identify people with RA who might benefit from
interventions that target non-inflammatory mechanisms
in order to improve their pain prognosis.
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